10 Best Multibagger Stocks to Buy According to Billionaires

3. ADMA Biologics, Inc. (NASDAQ:ADMA)

Number of Hedge Fund Holders: 37

Number of Billionaire Holders: 12

1-Year Gain as of April 22: 216.77%

ADMA Biologics, Inc. (NASDAQ:ADMA) is a biotechnology company that manufactures and commercializes speciality biologics to prevent and treat infectious diseases. The company also develops and commercializes plasma-derived products, including immune globulin therapies. It is one of the best multibagger stocks to buy, according to billionaires, going by the 216% gain over the past year. Likewise, Cantor Fitzgerald maintains an Overweight rating on the stock with a $25 price target.

Cantor Fitzgerald reiterated the buy stance while echoing the biopharmaceutical company pattern of issuing conservative revenue guidance. Last year, ADMA Biologics, Inc. (NASDAQ:ADMA) projected sales of $320 million only to deliver a 33% increase in sales to $426 million as of the end of the year. The research firm expects the company to deliver significant revenue growth in 2025 owing to expected growth in immunoglobulin therapy, ASCENIV, and the impact of high-titer plasma supply contracts.

Additionally, ADMA Biologics, Inc. (NASDAQ:ADMA) delivered impressive fourth-quarter and full-year 2024 results, underscoring success in the biopharmaceutical market. Revenue in the fourth quarter totalled $117.5 million against $113.4 million expected. On the other hand, full-year revenue increased 65% to $426.5 million as gross profit margins improved to 51.5%.